AD patients typically present with an increase in phosphodiesterase 4 which contributes to an increased production of inflammatory cytokines like IL-4 and IL-13, thus using PDE-4 inhibitors may reduce the number of inflammatory cytokines and reduce the disease severity [64]. Here, IL4 is linked to Alzheimer disease.